Inactive Instrument

Alterola Biotech, Inc. Stock Other OTC

Equities

ABTI

US02152V1035

Biotechnology & Medical Research

Sales 2022 - Sales 2023 - Capitalization 35.27M
Net income 2022 -6M Net income 2023 -1M EV / Sales 2022 -
Net Debt 2022 199K Net Debt 2023 1.41M EV / Sales 2023 -
P/E ratio 2022
-26.2 x
P/E ratio 2023
-20.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 56.4%
More Fundamentals * Assessed data
Dynamic Chart
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Alterola Biotech, Inc. Announces Executive Changes CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Alterola Biotech, Inc. Executive Changes CI
Alterola Biotech, Inc. Appoints Terry Rafih as A Member of Board of Directors CI
Bright Green Corporation completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl. CI
Sector Update: Health Care Stocks Rebound Slightly in Late Trade, Pare Losses MT
Sector Update: Health Care Stocks Dropping Tuesday Afternoon MT
Bright Green Corporation has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl for $4 million. CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 61 22-05-17
Chairman 60 21-06-20
Chief Operating Officer 57 21-06-20
Members of the board TitleAgeSince
Chief Executive Officer 61 22-05-17
Director/Board Member - 23-10-09
Director/Board Member 73 -
More insiders
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
More about the company